Axxcess Wealth Management LLC Purchases 1,618 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Axxcess Wealth Management LLC grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 18.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,551 shares of the medical equipment provider’s stock after buying an additional 1,618 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Intuitive Surgical were worth $4,211,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Freestone Capital Holdings LLC lifted its stake in shares of Intuitive Surgical by 2.9% in the 1st quarter. Freestone Capital Holdings LLC now owns 7,471 shares of the medical equipment provider’s stock worth $2,982,000 after purchasing an additional 208 shares during the period. CreativeOne Wealth LLC increased its holdings in Intuitive Surgical by 41.2% during the first quarter. CreativeOne Wealth LLC now owns 2,324 shares of the medical equipment provider’s stock valued at $927,000 after buying an additional 678 shares during the last quarter. Fayez Sarofim & Co raised its position in Intuitive Surgical by 6.6% in the first quarter. Fayez Sarofim & Co now owns 885,650 shares of the medical equipment provider’s stock worth $353,454,000 after acquiring an additional 54,700 shares during the period. MayTech Global Investments LLC boosted its stake in shares of Intuitive Surgical by 6.2% during the 1st quarter. MayTech Global Investments LLC now owns 53,709 shares of the medical equipment provider’s stock worth $21,435,000 after acquiring an additional 3,134 shares during the last quarter. Finally, Shell Asset Management Co. grew its position in shares of Intuitive Surgical by 6.9% during the 1st quarter. Shell Asset Management Co. now owns 32,662 shares of the medical equipment provider’s stock valued at $13,035,000 after acquiring an additional 2,095 shares during the period. Institutional investors own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ISRG shares. Citigroup lifted their price objective on shares of Intuitive Surgical from $462.00 to $512.00 and gave the company a “buy” rating in a research report on Wednesday, July 10th. Jefferies Financial Group boosted their target price on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. BTIG Research increased their price target on Intuitive Surgical from $451.00 to $459.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Morgan Stanley lifted their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Finally, Evercore ISI lowered their target price on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a research report on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and an average target price of $438.74.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $641,382.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, EVP Robert Desantis sold 376 shares of Intuitive Surgical stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $375.39, for a total value of $141,146.64. Following the completion of the transaction, the executive vice president now owns 5,507 shares in the company, valued at approximately $2,067,272.73. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Craig H. Barratt sold 1,400 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $641,382.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,358 shares of company stock worth $5,592,694. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Up 1.0 %

Shares of ISRG traded up $4.56 on Friday, reaching $441.30. The stock had a trading volume of 1,177,895 shares, compared to its average volume of 1,561,868. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $468.78. The firm has a market capitalization of $156.82 billion, a PE ratio of 78.83, a PEG ratio of 5.00 and a beta of 1.39. The firm has a 50-day moving average of $426.97 and a 200 day moving average of $397.30.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the prior year, the firm posted $1.18 earnings per share. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.